Atom Investors’s Passage Bio PASG Stock Holding History

Atom Investors’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,902	Closed	-$2.13M	–	598
2020 Q2	$2.13M	Sell	3,902 -3,598	-48%	-$1.62M	0.14%	130
2020 Q1	$2.36M	Buy	+7,500	New	+$2.35M	0.21%	101

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atom Investors's PASG Position: Q3 2020 in Review

Atom Investors sold out of Passage Bio (PASG) in Q3 2020, closing a stake of 3,902 shares — an estimated $2.13M sold.

Atom Investors first reported a position in PASG in Q1 2020 and held it in 2 quarters. The position peaked at $2.36M in Q1 2020. 70 funds tracked by Wall St. Rank hold PASG as of Q3 2020.

Atom Investors reported no remaining Passage Bio position as of Q3 2020 after selling out during the quarter.
Atom Investors sold 3,902 Passage Bio shares in Q3 2020, an estimated $2.13M.
Atom Investors first reported a position in Passage Bio in Q1 2020 and held it in 2 quarters.
Atom Investors's Passage Bio position peaked at $2.36M in Q1 2020.
70 funds tracked by Wall St. Rank held Passage Bio as of Q3 2020.

Based on Atom Investors's 13F filing for Q3 2020, filed 13 Nov 2020.